Jun 13, 2023 / 09:00PM GMT
Unidentified Company Representative -
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Jonathan, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Mark C. Johnson - ACADIA Pharmaceuticals Inc. - VP of IR
Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's ACP-101 program for the treatment of Prader-Willi syndrome. Joining me on the call today from ACADIA are Steve Davis, our President and Chief Executive Officer, who will provide some opening remarks on our ACP-101 program in Prader-Willi syndrome and our Levo Therapeutics acquisition before turning it over to Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will provide a more complete overview on the syndrome, ACP-101 and our Phase III program. Steve
ACADIA Pharmaceuticals Inc to Announce Phase 3 Development Candidate ACP-101 Call Transcript
Jun 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers